Page last updated: 2024-12-07
b 220
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
B 220: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 130705 |
CHEMBL ID | 456589 |
SCHEMBL ID | 1581068 |
MeSH ID | M0167296 |
Synonyms (24)
Synonym |
---|
2-(2,3-dimethylindolo[3,2-b]quinoxalin-6-yl)-n,n-dimethyl-ethanamine |
6h-indolo[2,3-b]quinoxaline-6-ethanamine, n,n,2,3-tetramethyl- |
OPREA1_679137 , |
B220 , |
CHEMBL456589 |
2-(2,3-dimethylindolo[3,2-b]quinoxalin-6-yl)-n,n-dimethylethanamine |
9-oh-b220 |
112228-65-6 |
b-220 |
6h-indolo(2,3-b)quinoxaline-6-ethanamine, n,n,2,3-tetramethyl- |
b 220 |
2,3-dimethyl-6-(dimethylaminoethyl)-9-hydroxy-6h-indolo-(2,3-b)quinoxaline |
2,3-dimethyl-n,n-dimethylaminoethyl-5h-indolo(2,3-b)quinoxaline |
SCHEMBL1581068 |
CS-0018424 |
HY-100272 |
DTXSID40920692 |
2-(2,3-dimethyl-6h-indolo[2,3-b]quinoxalin-6-yl)-n,n-dimethylethan-1-amine |
2,3-dimethyl-6(2-dimethylaminoethyl)-6h-indolo-(2,3-b)quinoxaline |
MS-24703 |
nsc-811922 |
112229-05-7 |
nsc811922 |
AKOS040732520 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID390367 | Antiviral activity against human cytomegalovirus | 2008 | Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24 | Interactions of antiviral indolo[2,3-b]quinoxaline derivatives with DNA. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 40.24
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.24) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |